Immunotherapeutic Technology Transfer Group

The role of the recently established group is to translate novel cell immunotherapy protocols from the laboratory to the clinic. For patients with acute myeloid leukemia (AML) with persistent or recurrent disease after transplantation or elderly patients a Natural Killer (NK) cell adoptive immunotherapy is currently developed. The manufactured NK cell based medicinal product should be able to directly kill leukemic cells and boost the immune system of a patient, when combined with the appropriate treatment protocol.

The results of the preclinical research, such as the cell preparation technology and efficacy measuring essays will be implemented under the GMP (Good Manufacturing Practice) pharmaceutical quality assurance system. The group prepares and tests the production and quality control processes, with direct output to manufacture and quality control Standard Operating Procedures (SOPs) and Validation Protocols. The Immunotherapeutic Technology Transfer Group closely cooperates with the Department of Immunotherapy and Immunotherapy group of IHBT.